Oxalate and the Kidneys: Primary Hyperoxaluria in Practice
This Exhibitor Spotlight session 'Oxalate and the Kidneys: Primary Hyperoxaluria in Practice' (supported by Alnylam Pharmaceuticals) will provide insights into a group of rare kidney disorders that have a significant impact on the lives of those affected – primary hyperoxaluria. Attendees will gain an understanding of how oxalate is at the core of primary hyperoxaluria pathophysiology, the current burden of disease for patients and affected families, and the benefit of identifying patients early in disease progression.
Hear from Michelle Amy Baum MD, a pediatric nephrologist from Boston Children's Hospital and Harvard Medical School with a special interest in rare kidney stone disorders, as she shares her specialist expertise and clinical experience, as well as her professional perspective on filmed patient testimonials.
This session will be available on demand throughout Kidney Week 2020 Reimagined and on the ASN website until 31 March 2021.
The Exhibitor Spotlight is not a Continuing Education (CE) activity.
This Exhibitor Spotlight is initiated and fully funded by Alnylam Pharmaceuticals and is for healthcare professionals.
MED-US-GO1-2000101│ September 2020